Targeting MiR-34a/ Interactions Partially Corrects Alveologenesis in Experimental Bronchopulmonary Dysplasia
Overview
Authors
Affiliations
Bronchopulmonary dysplasia (BPD) is a common complication of preterm birth characterized by arrested lung alveolarization, which generates lungs that are incompetent for effective gas exchange. We report here deregulated expression of miR-34a in a hyperoxia-based mouse model of BPD, where miR-34a expression was markedly increased in platelet-derived growth factor receptor (PDGFR)α-expressing myofibroblasts, a cell type critical for proper lung alveolarization. Global deletion of miR-34a; and inducible, conditional deletion of miR-34a in PDGFRα cells afforded partial protection to the developing lung against hyperoxia-induced perturbations to lung architecture. mRNA was identified as the relevant miR-34a target, and using a target site blocker , the miR-34a/ interaction was validated as a causal actor in arrested lung development. An antimiR directed against miR-34a partially restored PDGFRα myofibroblast abundance and improved lung alveolarization in newborn mice in an experimental BPD model. We present here the first identification of a pathology-relevant microRNA/mRNA target interaction in aberrant lung alveolarization and highlight the translational potential of targeting the miR-34a/ interaction to manage arrested lung development associated with preterm birth.
Xu P, Zhuo W, Zhang P, Chen Y, Du Y, Li Y Biomolecules. 2025; 15(1.
PMID: 39858495 PMC: 11764269. DOI: 10.3390/biom15010101.
Maeda H, Li X, Go H, Dennery P, Yao H Front Biosci (Landmark Ed). 2024; 29(7):271.
PMID: 39082345 PMC: 11799892. DOI: 10.31083/j.fbl2907271.
Loss of microRNA-30a and sex-specific effects on the neonatal hyperoxic lung injury.
Grimm S, Reddick S, Dong X, Leek C, Wang A, Gutierrez M Biol Sex Differ. 2023; 14(1):50.
PMID: 37553579 PMC: 10408139. DOI: 10.1186/s13293-023-00535-6.
/MicroRNA-34 axis in cancer and beyond.
Pan W, Chai B, Li L, Lu Z, Ma Z Heliyon. 2023; 9(4):e15155.
PMID: 37095919 PMC: 10121403. DOI: 10.1016/j.heliyon.2023.e15155.
Mizikova I, Thebaud B Mol Cell Pediatr. 2023; 10(1):4.
PMID: 37072570 PMC: 10113423. DOI: 10.1186/s40348-023-00158-2.